MedTrace Logo

A Pilot Study Assessing the Impact of Gilenya Therapy on Bone Density Change in Relapsing Forms of Multiple Sclerosis

NCT01811290 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 36

Last updated 2018-02-01

No results posted yet for this study

Summary

The purpose of this study is to assess whether Multiple Sclerosis patients treated with Gilenya show a beneficial change over time in bone mass density and bone turnover markers as compared to matched controls treated with alternative FDA approved therapy or no therapy.

Conditions

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Simnad, Virginia, M.D.

    lead INDIV

Principal Investigators

  • Virginia I Simnad, MD · Evergreen Hospital

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2018-07-31
Completion
2018-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01811290 on ClinicalTrials.gov